New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights

New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights

A novel radiopharmaceutical is demonstrating promising results in patients who have previously been treated with Pluvicto, signaling a potential shift in the advanced prostate cancer treatment paradigm. This development presents significant competitive implications for companies like Abivax, Fulcrum, Convergent, and Vera. The post-Pluvicto setting is fast becoming one of the most commercially consequential battlegrounds in oncology, and the early data reshaping this space demand immediate attention from analysts and BD teams tracking the next wave of radiopharmaceutical value creation.

Key Takeaways

• A novel radiopharmaceutical is generating encouraging clinical signals in patients who have progressed on or after Pluvicto, directly targeting one of the fastest-growing unmet needs in advanced prostate cancer.
• The PSMAddition clinical trial is providing the foundational evidence base for post-Pluvicto radiopharmaceutical development, with readouts that will shape competitive positioning across the sector.
• Companies including Abivax, Fulcrum, Convergent, and Vera must reassess R&D priorities, partnership strategies, and market positioning as the post-Pluvicto opportunity crystallizes.
• Novartis is simultaneously defending its Pluvicto franchise and advancing next-generation radiopharmaceutical candidates, raising the competitive bar for all other entrants.
• Subsequent therapy use after Pluvicto has climbed from roughly 30% in earlier treatment eras, underscoring the commercial significance of any agent that can demonstrate efficacy in this population.

Why Is the Post-Pluvicto Setting Suddenly the Most Watched Space in Prostate Cancer?

When the FDA approved [177Lu]Lu-PSMA-617 (Pluvicto) in March 2022, it validated PSMA-targeted radioligand therapy as a transformative modality for metastatic castration-resistant prostate cancer. The VISION trial established Pluvicto's clinical credibility, and real-world adoption has been swift. But success has created its own problem: a growing cohort of patients who have received — and progressed on — Pluvicto now needs subsequent therapy, a segment that barely existed three years ago.

That vacuum is what the current wave of radiopharmaceutical development is racing to fill. Early data from the PSMAddition clinical trial, highlighted in STAT's Readout newsletter, has shown that a novel radiopharmaceutical can generate meaningful clinical activity in precisely this post-Pluvicto population. The trial's readouts — including tumor response rates and safety profiles in heavily pre-treated patients — are providing the first real evidence that sequential PSMA-targeted therapy is viable, a concept that was largely theoretical when Pluvicto first launched.

Novartis itself is not ceding this space. The company recently reported that an experimental radiopharmaceutical reduced tumor markers in 40% of advanced prostate cancer patients in an early study, according to Reuters. This positions the originator of Pluvicto as both incumbent and potential disruptor — a dual role that complicates every competitor's market model. If Novartis can capture the post-Pluvicto segment with its own next-generation agent, the window for independent challengers narrows considerably.

The companies named in STAT's Readout — Abivax, Fulcrum, Convergent, and Vera — occupy different positions in this evolving market. Abivax recently reported positive ulcerative colitis data that was weighed down by cancer concerns, creating a complex pipeline narrative. Fulcrum shelved its sickle cell drug, leaving the company in a period of strategic recalibration. Convergent and Vera operate in adjacent therapeutic spaces where radiopharmaceutical convergence is increasingly attractive, but neither has a declared radiopharmaceutical program targeting the post-Pluvicto population specifically. This makes the emerging competitive data from PSMAddition directly relevant to their BD and platform strategy decisions.

How Should Abivax, Fulcrum, Convergent, and Vera Benchmark Against This Emerging Competitor?

The strategic calculus differs for each company, but the core question is the same: does a promising post-Pluvicto radiopharmaceutical accelerate or diminish the commercial opportunity for their respective pipelines?

For Abivax, the answer hinges on pipeline flexibility. The company's core value driver remains its ulcerative colitis program, but the competitive dynamics of the post-Pluvicto space could inform its BD strategy if the company identifies platform technologies or assets repositionable for oncology. The key benchmark is whether Abivax's existing infrastructure can support a credible radiopharmaceutical play, or whether a partnership or licensing deal is the more capital-efficient path.

Fulcrum is in a more fluid position. Having scrapped its sickle cell asset, the company has both the need and the bandwidth to redirect its precision medicine expertise toward new opportunities. The post-Pluvicto setting is directly relevant: Fulcrum should be benchmarking any prospective acquisition or collaboration against the efficacy signals emerging from PSMAddition, paying particular attention to response durability and safety in patients who have already endured multiple lines of therapy. If the PSMAddition data show a clean safety profile with durable responses, the risk calculus for entering this space shifts favorably.

Convergent and Vera face a platform-level decision. Both companies have capabilities that could be adapted to radiopharmaceutical development — novel targeting mechanisms, biomarker-driven patient selection, or combination approaches that address PSMA heterogeneity, which is likely more prevalent in post-Pluvicto tumors. The critical benchmark for both is whether their platforms can differentiate against Novartis's vertically integrated radiopharmaceutical operation, which controls everything from isotope supply to commercial distribution. Partnerships with established radiopharmaceutical manufacturers could accelerate time to market, but at the cost of margin and control.

The broader takeaway is that the post-Pluvicto setting is no longer a theoretical TAM expansion story. It is a clinical reality with a growing patient pool, and companies without a credible strategy for this segment risk being marginalized as the next phase of radiopharmaceutical commercialization unfolds.

What Is the Clinical and Commercial Trajectory for Post-Pluvicto Radiopharmaceuticals?

Durability of response will be the primary clinical gating factor. Pluvicto demonstrated a 59% reduction in the risk of radiographic disease progression in its pivotal program — a high bar for any successor. If the emerging radiopharmaceutical can show comparable or superior outcomes in a more heavily pre-treated population, the commercial case becomes compelling. Early data from PSMAddition will be scrutinized not just for response rates but for the depth and duration of those responses, which will directly influence prescribing behavior and payer coverage decisions.

The regulatory pathway could compress timelines considerably. The FDA has shown willingness to accelerate oncology approvals for therapies addressing clear unmet needs, and a post-Pluvicto indication could qualify for breakthrough therapy designation or priority review. The PSMAddition study registered on ClinicalTrials.gov provides a public-facing timeline that analysts can track for enrollment milestones, primary completion dates, and readouts. Any PSMAddition press release that signals an accelerated regulatory filing would compress the competitive window and force faster strategic decisions from companies evaluating this space.

Commercial execution will be just as important as clinical data. Pluvicto's own launch was temporarily constrained by manufacturing and isotope supply challenges — logistical hurdles that any new entrant must proactively address. Companies with established radiopharmaceutical manufacturing capabilities or secured actinium-225 or lutetium-177 supply chains will have a meaningful advantage in speed to market and reliability of supply, both of which influence formulary adoption and physician confidence.

The addressable market is substantial and growing. As Pluvicto penetrates earlier lines of therapy — supported by data showing benefit in combination with hormone therapy — the absolute number of patients who eventually progress and need subsequent treatment will expand dramatically. Success in the post-Pluvicto niche could also serve as a platform for expansion into other tumor types, amplifying the long-term value of any asset that establishes a foothold now.

Combination strategies represent the next frontier. Pluvicto has shown promise in combination with standard treatments, and the next generation of radiopharmaceuticals will likely be evaluated alongside immunotherapy, androgen receptor pathway inhibitors, and DNA repair inhibitors. Companies that can demonstrate synergistic efficacy through rational combinations will capture disproportionate market share — and this is where Convergent and Vera, with their platform-oriented approaches, could find their most credible entry point.

Frequently Asked Questions

Related profiles

• PLUVICTO
• Fulcrum
• Vera

Related coverage

• Duchesnay Pharmaceutical Group's Growth Trajectory Five Years Post-Acquisition
• FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
• STAT+ Report: Corporate Medicine Crackdown Threatens Telehealth Business Models